Gene · 54890
NIH grants903
NIH grants whose papers are about the gene, through NIH's grant-paper links.
121 to 140 of 903
Download this page as JSON| Grant | Title | ALKBH5 papers | Newest fiscal year |
|---|---|---|---|
| R01AI134988 | Long noncoding RNA expressing genomic elements that control antibody diversification and chromosomal integrity in B cells | 1 | 2025 |
| R01CA157644 | Central tolerance mechanisms in B-cell malignancies | 1 | 2025 |
| R01CA163217 | Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma | 1 | 2025 |
| R01CA196703 | Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma | 1 | 2025 |
| R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 1 | 2025 |
| R01CA205247 | Targeting MicroRNAs to Eradicate Leukemia Stem Cells | 1 | 2025 |
| R01CA207209 | Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism | 1 | 2025 |
| R01CA225958 | Novel bioengineered microRNA therapeutics for lung cancer | 1 | 2025 |
| R01CA244360 | Using dietary glutamine supplementation for melanoma prevention and targeted therapy | 1 | 2025 |
| R01CA246130 | Dissecting and Targeting RB1-Mutant Osteosarcoma | 1 | 2025 |
| R01CA253981 | Modeling myelodysplasia | 1 | 2025 |
| R01CA256741 | A non-canonical role for EZH2 in rRNA methtlation | 1 | 2025 |
| R01CA256833 | BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer | 1 | 2025 |
| R01CA257520 | A deubiquitination module controls Treg adaptation to tumor microenvironment | 1 | 2025 |
| R01CA258589 | Small molecules to target the RNA methyltransferase complex METTL3/METTL14 | 1 | 2025 |
| R01CA262316 | Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cells | 1 | 2025 |
| R01CA266604 | Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML | 1 | 2025 |
| R01CA268998 | Tumor suppressor reprogramming by EBV through post-translational modification | 1 | 2025 |
| R01CA271915 | Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer | 1 | 2025 |
| R01DK046335 | Probing the biochemical mechanism of amyloid disease | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/grants?page=7